JP2003040763A - Polyhydric alcohol-containing ointment base - Google Patents
Polyhydric alcohol-containing ointment baseInfo
- Publication number
- JP2003040763A JP2003040763A JP2002117749A JP2002117749A JP2003040763A JP 2003040763 A JP2003040763 A JP 2003040763A JP 2002117749 A JP2002117749 A JP 2002117749A JP 2002117749 A JP2002117749 A JP 2002117749A JP 2003040763 A JP2003040763 A JP 2003040763A
- Authority
- JP
- Japan
- Prior art keywords
- polyethylene glycol
- ointment base
- glycol
- polyhydric alcohol
- ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003883 ointment base Substances 0.000 title claims abstract description 30
- 150000005846 sugar alcohols Polymers 0.000 title claims abstract description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 27
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 239000007787 solid Substances 0.000 claims abstract description 14
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 17
- 238000002844 melting Methods 0.000 claims description 15
- 230000008018 melting Effects 0.000 claims description 15
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002674 ointment Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 15
- 238000007790 scraping Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- -1 eye muscle regulator Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 229960005040 miconazole nitrate Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、軟膏剤基剤に関
し、さらに詳しくは常温で液体状の多価アルコール及び
固体状のポリエチレングリコールを含有し、熱安定性及
び使用感に優れた軟膏剤基剤に関する。TECHNICAL FIELD The present invention relates to an ointment base, and more particularly to an ointment base containing polyhydric alcohol which is liquid at room temperature and polyethylene glycol which is solid, and which is excellent in thermal stability and usability. Regarding agents.
【０００２】[0002]
【背景技術】従来の軟膏剤基剤のうち油性のものは水で
洗い流すことができず、一方、クリームのような水性の
ものにあっては、熱安定性が悪く、また、界面活性剤を
必須成分とするため、皮膚に刺激を与える等の欠点を有
していた。[Background Art] Among the conventional ointment bases, oily ones cannot be washed off with water, while water-based ones such as cream have poor heat stability and a surfactant. Since it is an essential component, it has drawbacks such as irritation to the skin.
【０００３】これに対して局方マクロゴール軟膏は、水
溶性であって、熱安定性にも優れるが、軟膏剤の基剤と
しては硬くて延びが悪い等の問題点を有していた。On the other hand, the pharmacopoeia macrogol ointment is water-soluble and is excellent in heat stability, but it has a problem that it is hard and has poor spread as a base of an ointment.
【０００４】[0004]
【発明が解決しようとする課題】そこで、本発明は、皮
膚刺激性がなく、水溶性で、熱安定性に優れ、かつ、良
好な使用感を有する軟膏剤基剤を提供することを課題と
する。SUMMARY OF THE INVENTION It is therefore an object of the present invention to provide an ointment base which has no skin irritation, is water-soluble, has excellent thermal stability, and has a good feeling in use. To do.
【０００５】[0005]
【課題を解決するための手段】本発明者らは、前記課題
を解決すべく鋭意検討を重ねた結果、常温で液体状の多
価アルコールに一定量の常温で固体状のポリエチレング
リコールを混合・融解させた軟膏剤基剤が、皮膚刺激性
がなく、水溶性で、熱安定性にも優れ、良好な使用感を
有することを見出し、本発明を完成するに至った。Means for Solving the Problems As a result of intensive studies to solve the above problems, the present inventors have found that a polyhydric alcohol that is liquid at room temperature is mixed with a fixed amount of polyethylene glycol that is solid at room temperature. The inventors have found that the melted ointment base has no skin irritation, is water-soluble, has excellent thermal stability, and has a good feeling in use, and has completed the present invention.
【０００６】すなわち、本発明は、25℃で液体状の多価
アルコールを基剤全体の60〜90質量％含有する軟膏剤基
剤において、該多価アルコール１質量部に対して25℃で
固体状のポリエチレングリコールを0.11〜0.66質量部含
有することを特徴とする軟膏剤基剤である。That is, the present invention relates to an ointment base containing 60 to 90% by mass of a polyhydric alcohol in a liquid state at 25 ° C., which is a solid at 25 ° C. with respect to 1 part by mass of the polyhydric alcohol. An ointment base characterized by containing 0.11 to 0.66 parts by mass of polyethylene glycol.
【０００７】本発明における25℃で液体状の多価アルコ
ールとは、１分子中にアルコール性水酸基を２個以上も
つ有機化合物であって、25℃において液体状のものをい
う。このような多価アルコールとしては、25℃で液体状
のポリエチレングリコール、プロピレングリコール、ジ
プロピレングリコール、１，３−ブチレングリコール、
グリセリン、エチレングリコール、ジエチレングリコー
ル及びトリエチレングリコールが挙げられる。これらの
中でも皮膚刺激性が小さいポリエチレングリコール、
１，３−ブチレングリコールが好ましい。The polyhydric alcohol which is liquid at 25 ° C. in the present invention means an organic compound having two or more alcoholic hydroxyl groups in one molecule, which is liquid at 25 ° C. Such polyhydric alcohols include liquid polyethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol at 25 ° C,
Glycerin, ethylene glycol, diethylene glycol and triethylene glycol are mentioned. Among them, polyethylene glycol, which has low skin irritation
1,3-butylene glycol is preferred.
【０００８】これら多価アルコールは、基剤中に通常60
〜90質量％含有することを要し、使用感という点では基
剤は軟らかい方がよいので、70〜90質量％を含有するこ
とが好ましく、80〜90質量％を含有することがさらに好
ましい。特に液体状のポリエチレングリコールにあって
は、基剤中に70質量％以上存することが軟膏剤基剤とし
たときの使用感を向上させ、好ましいといえる。These polyhydric alcohols usually contain 60
It is preferable that the content of the base be up to 90% by mass, and the base is softer from the viewpoint of feeling in use. Therefore, it is preferably 70 to 90% by mass, and more preferably 80 to 90% by mass. Particularly in the case of liquid polyethylene glycol, it can be said that the presence of 70% by mass or more in the base improves the feeling of use when used as an ointment base, and is therefore preferable.
【０００９】これら多価アルコールは１種のみを用いて
もよいが、２種以上を組み合わせて用いてもよい。These polyhydric alcohols may be used alone or in combination of two or more.
【００１０】上記多価アルコール中、25℃で液体状のポ
リエチレングリコールとは、平均分子量が200〜600の範
囲にあるポリエチレングリコールをいうが、軟膏基剤と
したときの使用感の点からは、平均分子量が300〜400の
範囲にあるものが好ましい。Polyethylene glycol in liquid form at 25 ° C. in the above polyhydric alcohol means polyethylene glycol having an average molecular weight in the range of 200 to 600, but from the viewpoint of feeling when used as an ointment base, Those having an average molecular weight in the range of 300 to 400 are preferable.
【００１１】また、本発明において25℃で固体状のポリ
エチレングリコールとは、平均分子量が4000〜20000の
範囲にあるポリエチレングリコールをいうが、軟膏剤と
したときの使用感を良好に保持し、熱安定性を向上させ
るという点からは、平均分子量が4000〜6000の範囲にあ
るものが好ましい。In the present invention, solid polyethylene glycol at 25 ° C. refers to polyethylene glycol having an average molecular weight in the range of 4,000 to 20,000, which retains a good feeling when used as an ointment and From the viewpoint of improving stability, those having an average molecular weight in the range of 4000 to 6000 are preferable.
【００１２】ここで、半固体状のポリエチレングルコー
ル（例えば、平均分子量1500のもの）を使用した場合に
は、単独では熱安定性が悪く、液体状のポリエチレング
リコールと組み合わせると融点が低下し、熱安定性がさ
らに悪化する。一方、固体状のポリエチレングリコール
と組み合わせると熱安定性は改善されるが、硬すぎて軟
膏剤の基剤としては充分に機能しない。Here, when semi-solid polyethylene glycol (for example, having an average molecular weight of 1500) is used, it has poor thermal stability when used alone, and when it is combined with liquid polyethylene glycol, the melting point decreases, Thermal stability is further deteriorated. On the other hand, when it is combined with solid polyethylene glycol, the thermal stability is improved, but it is too hard to sufficiently function as a base for an ointment.
【００１３】よって、ポリエチレングリコールのみによ
って本発明にかかる軟膏剤基剤を得るには、液体状のも
のと固体状のものとを組み合わせることが必須となる。
なお、ポリエチレングリコールの平均分子量は、日本薬
局方記載のマクロゴールの平均分子量測定法により求め
た値である。Therefore, in order to obtain the ointment base according to the present invention using only polyethylene glycol, it is essential to combine the liquid form and the solid form.
The average molecular weight of polyethylene glycol is a value determined by the average molecular weight measurement method of macrogol described in the Japanese Pharmacopoeia.
【００１４】本発明における軟膏剤基剤は25℃で液体状
の多価アルコールと固体状のポリエチレングリコールを
ともに含有するものであって、その割合は、25℃で液体
状の多価アルコール１質量部に対して25℃で固体状のポ
リエチレングリコールを通常0.11〜0.66質量部、軟膏剤
としたときの使用感を良好に保持し、熱安定性を向上さ
せるという点からは、0.2〜0.5質量部含有させることが
好ましく、0.3〜0.4質量部含有させることがさらに好ま
しい。The ointment base in the present invention contains both polyhydric alcohol in liquid form at 25 ° C. and polyethylene glycol in solid form, the ratio of which is 1 mass of polyhydric alcohol in liquid form at 25 ° C. 0.21 to 0.66 parts by mass of solid polyethylene glycol at 25 ° C. relative to 20 parts by weight, 0.2 to 0.5 parts by mass from the viewpoint of maintaining good feeling when used as an ointment and improving thermal stability. It is preferably contained, and more preferably 0.3 to 0.4 parts by mass.
【００１５】本発明における軟膏剤基剤は、ＤＳＣ（di
fferential scanning calorimeter、示差走査熱量測定
装置）などの融点測定装置を用い、走査速度を毎分1.0
℃に設定して昇温させたときの融解開始温度が40℃以上
であって、かつ、融解ピーク温度が40〜55℃の範囲内に
あることを特徴とする。というのも、軟膏剤としたとき
の熱安定性という点では、融解開始温度が40℃以上であ
ることを要し、使用感という点では、融解ピーク温度が
40〜55℃の範囲内にあることが望ましいからである。The ointment base in the present invention is a DSC (di
fferential scanning calorimeter, differential scanning calorimeter)
It is characterized in that the melting start temperature is 40 ° C. or higher when the temperature is set to 0 ° C. and the temperature is raised, and the melting peak temperature is in the range of 40 to 55 ° C. In terms of thermal stability when used as an ointment, the melting start temperature must be 40 ° C or higher, and in terms of feeling of use, the melting peak temperature is
It is preferable that the temperature is within the range of 40 to 55 ° C.
【００１６】[0016]
【発明の実施の形態】本発明における軟膏剤基剤は、25
℃で液体状のポリエチレングリコールに一定量の25℃で
固体状のポリエチレングリコールをホモミキサーに入れ
て、混合・融解させ、混合物の融点以下まで攪拌しなが
ら冷却することによって調製できる。また、この基剤中
に有効成分を溶解・分散させることによって軟膏剤とす
ることができる。その際、熱安定性や使用感を損なわな
いように他の軟膏剤基剤を混合、溶解等させてもよい。BEST MODE FOR CARRYING OUT THE INVENTION The ointment base of the present invention is 25
It can be prepared by adding a certain amount of solid polyethylene glycol at 25 ° C. to a liquid polyethylene glycol at a temperature of a homomixer, mixing and melting the mixture, and cooling to a melting point of the mixture or lower with stirring. Moreover, an ointment can be prepared by dissolving and dispersing the active ingredient in this base. At that time, other ointment bases may be mixed, dissolved, or the like so as not to impair the thermal stability and the feeling of use.
【００１７】本発明の軟膏剤基剤に配合しうる有効成分
は、多価アルコールと反応して沈殿を生じるような薬物
（例えば、ヨード、フェノール、クレゾール、レゾルシ
ン、サリチル酸、タンニン等）でなければ、特に限定は
ない。このような有効成分としては、抗菌剤、抗真菌
剤、抗ウイルス剤、抗炎症剤、鎮痛剤、発毛剤、抗ヒス
タミン剤、局所麻酔剤、収斂剤、組織修復剤、角質軟化
剤、鎮痒剤、保湿剤、アトピー性皮膚炎治療剤、血管収
縮剤、眼筋調節剤、抗アレルギー剤、角膜修復剤、清涼
化剤、ホルモン系薬物、血管拡張剤、美白剤、その他、
タンパク質系薬物、ペプチド系薬物、遺伝子系薬物、セ
ラミド系薬物、アミノ酸系薬物、抗しわ剤、酸素除去
剤、抗生物質、抗座瘡剤、創傷、火傷もしくは損傷治療
剤、各種グロースファクター、ビタミンなどが挙げられ
る。The active ingredient which can be blended with the ointment base of the present invention is a drug (eg iodine, phenol, cresol, resorcin, salicylic acid, tannin, etc.) which reacts with polyhydric alcohol to cause precipitation. There is no particular limitation. Such active ingredients include antibacterial agents, antifungal agents, antiviral agents, anti-inflammatory agents, analgesics, hair growth agents, antihistamines, local anesthetics, astringents, tissue repair agents, keratin softeners, antipruritic agents, Moisturizer, atopic dermatitis treatment agent, vasoconstrictor, eye muscle regulator, anti-allergic agent, corneal repair agent, refreshing agent, hormonal drug, vasodilator, whitening agent, etc.
Protein drugs, peptide drugs, gene drugs, ceramide drugs, amino acid drugs, anti-wrinkle agents, oxygen scavengers, antibiotics, anti-acne agents, wound, burn or injury therapeutic agents, various growth factors, vitamins, etc. Is mentioned.
【００１８】本発明の軟膏剤基剤以外に配合しうる基剤
としては、溶解補助剤、炭化水素、界面活性剤、抗酸化
剤、乳化安定剤、ゲル化剤、粘着剤等、各種動植物から
の抽出物、ｐＨ調節剤、防腐剤、キレート剤、香料、色
素などを本発明の作用を損なわない範囲で配合すること
ができる。特にエタノール等の低級アルコールは本発明
の作用を損なわないばかりか、基剤の殺菌性を高め、異
臭の発生を防止する等の効果を有するので、配合するこ
とが好ましい基剤成分である。Bases which can be blended in addition to the ointment base of the present invention include solubilizers, hydrocarbons, surfactants, antioxidants, emulsion stabilizers, gelling agents, adhesives, etc. from various animals and plants. The extract, pH adjuster, preservative, chelating agent, fragrance, dye and the like can be added within a range that does not impair the action of the present invention. In particular, lower alcohols such as ethanol not only impair the action of the present invention, but also have the effects of increasing the sterilization property of the base and preventing the generation of offensive odors, etc., so that it is a preferable base component to be blended.
【００１９】本発明の軟膏剤基剤は、これに水を配合し
なければ実質的には無水であり、水に不安定な有効成分
を含有する軟膏剤の基剤として特に有用性が高い。The ointment base of the present invention is substantially anhydrous unless it is mixed with water, and is particularly useful as a base for an ointment containing an active ingredient unstable to water.
【００２０】[0020]
【実施例】以下に、実施例及び試験例を挙げて本発明を
さらに詳細に説明する。EXAMPLES The present invention will be described in more detail below with reference to examples and test examples.
【００２１】（実施例１）
塩化ベンゼトニウム（抗菌剤） １ｇ
1,3-フ゛チレンク゛リコール ７０ｇホ゜リエチレンク゛リコール
4000 ２９ｇホ゜リエチレンク゛リコール
4000を卓上ホモミキサー（T.K.アヂホモ
ミクサー2M-03型，特殊機化工業（株））用容器に入
れ、掻き取りミキサーで攪拌しながら60℃で融解させ
た。これに予め塩化ベンゼトニウムを分散させておいた
1,3-フ゛チレンク゛リコールを添加し、脱気後、8000rpmで３分間ホ
モジナイズし、均一化させた。掻き取りミキサーで攪拌
しながら室温まで冷却し、軟膏剤を調製した。Example 1 Benzethonium Chloride (Antibacterial Agent) 1 g 1,3-butylene glycol 70 g Polyethylene glycol 4000 29 g Polyethylene glycol 4000 for tabletop homomixer (TK Aji Homomixer 2M-03, Tokushu Kika Kogyo Co., Ltd.) It was put in a container and melted at 60 ° C. with stirring with a scraping mixer. Benzethonium chloride was previously dispersed in this
After adding 1,3-butylene glycol and degassing, the mixture was homogenized at 8000 rpm for 3 minutes to homogenize it. While stirring with a scraping mixer, the mixture was cooled to room temperature to prepare an ointment.
【００２２】
（実施例２）
硝酸ミコナゾール（抗真菌剤） ０．５ｇ
ホ゜リエチレンク゛リコール400 ８９．５ｇ
ホ゜リエチレンク゛リコール6000 １０ｇホ゜リエチレンク゛リコール
6000を卓上ホモミキサー用容器に入れ、
掻き取りミキサーで攪拌しながら65℃で融解させた。こ
れに予め硝酸ミコナゾールを分散させておいたホ゜リエチレンク
゛リコール400を添加し、脱気後、8000rpmで３分間ホモジナ
イズし、均一化させた。掻き取りミキサーで攪拌しなが
ら室温まで冷却し、軟膏剤を調製した。Example 2 Miconazole Nitrate (Antifungal Agent) 0.5 g Polyethylene Glycol 400 89.5 g Polyethylene Glycol 6000 10 g Polyethylene Glycol 6000 was placed in a tabletop homomixer container,
It was melted at 65 ° C. with stirring with a scraping mixer. Polyethylene glycol 400 in which miconazole nitrate was previously dispersed was added to this, and after deaeration, homogenized at 8000 rpm for 3 minutes to homogenize. While stirring with a scraping mixer, the mixture was cooled to room temperature to prepare an ointment.
【００２３】（実施例３）
アシクロビル（抗ウィルス薬） ５ｇホ゜リエチレンク゛リコール
400 ７０ｇホ゜リエチレンク゛リコール
4000 ２５ｇホ゜リエチレンク゛リコール
4000を卓上ホモミキサー用容器に入れ、
掻き取りミキサーで攪拌しながら60℃で融解させた。こ
れに予めアシクロビルを分散させておいたホ゜リエチレンク゛リコー
ル400を添加し、脱気後、8000rpmで３分間ホモジナイズ
し、均一化させた。掻き取りミキサーで攪拌しながら室
温まで冷却し、軟膏剤を調製した。Example 3 Acyclovir (antiviral drug) 5 g Polyethylene Glycol 400 70 g Polyethylene Glycol 4000 25 g Polyethylene Glycol 4000 was placed in a container for a tabletop homomixer,
It was melted at 60 ° C. with stirring with a scraping mixer. Polyethylene glycol 400 in which acyclovir had been dispersed was added thereto, and after deaeration, homogenized at 8000 rpm for 3 minutes to homogenize. While stirring with a scraping mixer, the mixture was cooled to room temperature to prepare an ointment.
【００２４】（実施例４）
インドメタシン（抗炎症剤） １ｇ
1,3-フ゛チレンク゛リコール ７０ｇホ゜リエチレンク゛リコール
4000 ２９ｇホ゜リエチレンク゛リコール
4000を卓上ホモミキサー用容器に入れ、
掻き取りミキサーで攪拌しながら60℃で融解させた。こ
れに予めアシクロビルを分散させておいた1,3-フ゛チレンク゛リ
コールを添加し、脱気後、8000rpmで３分間ホモジナイズ
し、均一化させた。掻き取りミキサーで攪拌しながら室
温まで冷却し、軟膏剤を調製した。(Example 4) Indomethacin (anti-inflammatory agent) 1 g 1,3-butylene glycol 70 g Polyethylene glycol 4000 29 g Polyethylene glycol 4000 was placed in a container for a tabletop homomixer,
It was melted at 60 ° C. with stirring with a scraping mixer. To this, 1,3-butylene glycol in which acyclovir had been dispersed was added, and after deaeration, homogenized at 8000 rpm for 3 minutes to homogenize. While stirring with a scraping mixer, the mixture was cooled to room temperature to prepare an ointment.
【００２５】（実施例５）クロルフェニラミンマレイン
酸塩（抗ヒスタミン薬） １ｇホ゜リエチレンク゛リコール
400 ８９ｇホ゜リエチレンク゛リコール
6000 １０ｇホ゜リエチレンク゛リコール
6000を卓上ホモミキサー用容器に入れ、
掻き取りミキサーで攪拌しながら65℃で融解させた。こ
れに予めクロルフェニラミンマレイン酸塩を分散させておいたホ゜リエチレン
ク゛リコール400を添加し、脱気後、8000rpmで３分間ホモジナ
イズし、均一化させた。掻き取りミキサーで攪拌しなが
ら室温まで冷却し、軟膏剤を調製した。Example 5 Chlorpheniramine Maleate (Antihistamine) 1 g Polyethylene Glycol 400 89 g Polyethylene Glycol 6000 10 g Polyethylene Glycol 6000 was placed in a container for a tabletop homomixer,
It was melted at 65 ° C. with stirring with a scraping mixer. Polyethylene glycol 400 in which chlorpheniramine maleate had been previously dispersed was added to this, and after deaeration, homogenized at 8000 rpm for 3 minutes to homogenize. While stirring with a scraping mixer, the mixture was cooled to room temperature to prepare an ointment.
【００２６】
（実施例６）
シクロスポリンＡ（免疫抑制剤） ０．５ｇ
ホ゜リエチレンク゛リコール400 ８０ｇ
ホ゜リエチレンク゛リコール4000 １９．５ｇホ゜リエチレンク゛リコール
4000を卓上ホモミキサー用容器に入れ、
掻き取りミキサーで攪拌しながら60℃で融解させた。こ
れに予めシクロスポリンＡを分散させておいたホ゜リエチレンク
゛リコール400を添加し、脱気後、8000rpmで３分間ホモジナ
イズし、均一化させた。掻き取りミキサーで攪拌しなが
ら室温まで冷却し、軟膏剤を調製した。Example 6 Cyclosporin A (immunosuppressive agent) 0.5 g Polyethylene Glycol 400 80 g Polyethylene Glycol 4000 19.5 g Polyethylene Glycol 4000 was placed in a container for a tabletop homomixer,
It was melted at 60 ° C. with stirring with a scraping mixer. Polyethylene glycol 400 in which cyclosporin A had been dispersed was added thereto, and after deaeration, homogenized at 8000 rpm for 3 minutes to homogenize. While stirring with a scraping mixer, the mixture was cooled to room temperature to prepare an ointment.
【００２７】
（実施例７）
酢酸ヒドロコルチゾン（ステロイド抗炎症剤） ０．５ｇ
1,3-フ゛チレンク゛リコール ５５．０ｇ
濃グリセリン １０．０ｇ
ホ゜リエチレンク゛リコール4000 ２４．５ｇ
エタノール １０．０ｇホ゜リエチレンク゛リコール
4000を卓上ホモミキサー用容器に入れ、
掻き取りミキサーで攪拌しながら60℃で融解させた。こ
れに予め酢酸ヒドロコルチゾンを分散させておいた1,3-
フ゛チレンク゛リコールとグリセリンの混合物を添加し、脱気後、
ホッパーからエタノールを添加し、8000rpmで３分間ホ
モジナイズし、均一化させた。掻き取りミキサーで攪拌
しながら室温まで冷却し、軟膏剤を調製した。Example 7 Hydrocortisone acetate (steroid anti-inflammatory agent) 0.5 g 1,3-butylene glycol 55.0 g Concentrated glycerin 10.0 g Polyethylene glycol 4000 24.5 g Ethanol 10.0 g Polyethylene glycol 4000 on a tabletop homomixer In a container,
It was melted at 60 ° C. with stirring with a scraping mixer. Hydrocortisone acetate was previously dispersed in this solution.
After adding a mixture of butylene glycol and glycerin and degassing,
Ethanol was added from the hopper and homogenized at 8000 rpm for 3 minutes to homogenize. While stirring with a scraping mixer, the mixture was cooled to room temperature to prepare an ointment.
【００２８】（試験例１） 融解温度測定試験
表１に掲げた各種多価アルコール及び固体状のポリエチ
レングリコールをホモミキサーで混合・融解させた後に
冷却し、軟膏剤基剤を調製した。各々の軟膏剤基剤につ
いて、ＤＳＣ測定装置（ＤＳＣ７シリーズ，パーキン・
エルマー社製）により毎分1.0℃で昇温させたときの融
解状態を調べた。融解曲線を図１に示す。(Test Example 1) Melting Temperature Measurement Test Various polyhydric alcohols and solid polyethylene glycol listed in Table 1 were mixed and melted with a homomixer and then cooled to prepare an ointment base. For each ointment base, DSC measuring device (DSC7 series, Perkin
Elmer) was used to examine the melting state when the temperature was raised at 1.0 ° C./min. The melting curve is shown in FIG.
【００２９】[0029]
【表１】 [Table 1]
【００３０】（試験例２） 使用感試験
男性10名及び女性10名の計20名のパネラーを対象に、試
験例１で調製した軟膏剤基剤について、その使用感を表
２の基準で評価した。結果を表３に示す。(Test Example 2) Usability test For the ointment base prepared in Test Example 1, the usability was evaluated according to the criteria of Table 2 for a total of 20 panelists, 10 male and 10 female. did. The results are shown in Table 3.
【００３１】[0031]
【表２】 [Table 2]
【００３２】[0032]
【表３】 [Table 3]
【００３３】試験例１及び２より、実験例１乃至４で
は、融解開始温度が40℃以上であり、肌での延びも良好
であることから、熱安定性に優れ、使用感のよい軟膏剤
基剤であることがわかる。一方、対照例１では融解開始
温度は40℃以上であり、熱安定性には問題ないが、使用
感が芳しくないことがわかる。From Test Examples 1 and 2, in Experimental Examples 1 to 4, the melting start temperature was 40 ° C. or higher and the spread on the skin was good, so that the ointment was excellent in thermal stability and had a good feeling in use. It can be seen that it is a base. On the other hand, in Comparative Example 1, the melting start temperature is 40 ° C. or higher, and it is understood that the thermal stability is not a problem, but the usability is not good.
【００３４】（試験例３） ウサギ皮膚一次刺激性試験
薬物投与前日にウサギ（SPFウサギ，日本白色種，雄，1
1週齢）の背部を電気バリカンで除毛し、表４に記載の
実験例５及び対照例７の検体0.3mL（１mLテ゛ィスホ゜シリンシ゛使
用）ずつを動物用パッチテスト用絆創膏（鳥居薬品
（株）１インチ平方）に塗布して貼付した。投与部位を
保護するため粘着テープで覆い、アニマルジャケットを
24時間装着させた。なお、１群は４匹とした。Test Example 3 Rabbit Skin Primary Irritation Test Rabbit (SPF rabbit, Japanese white, male, 1 day before the drug administration
1 week old) was shaved with an electric hair clipper, and 0.3 mL each of the samples of Experimental Example 5 and Control Example 7 shown in Table 4 (using 1 mL of discharge ring) was applied to a patch test patch for animals (Torii Pharmaceutical Co., Ltd.). 1 inch square) was applied and affixed. To protect the administration site, cover it with adhesive tape and attach the animal jacket.
I put it on for 24 hours. In addition, there were four animals in one group.
【００３５】投与後24時間経過時にアニマルジャケット
を脱がせ、絆創膏を剥がし、微温湯を浸した脱脂綿で投
与部位を清拭し、紅斑及び浮腫の状態をそれぞれ表５に
記載のDraize法により数値化した。さらにそれより４８
時間経過後（投与後７２時間経過時）の紅斑及び浮腫の
状態を同様の方法により数値化した。そして、Draize法
により求めた値を下記式に代入し、一次刺激性インデッ
クス（P.I.I.：Primary Irritation Index）を算出し
た。以上の結果を表６に示す。なお、P.I.I.値が小さい
ほど皮膚刺激性は小さいことを表す。24 hours after the administration, the animal jacket was removed, the bandage was peeled off, the administration site was wiped with absorbent cotton soaked in lukewarm water, and the erythema and edema states were quantified by the Draize method shown in Table 5, respectively. 48 more
The state of erythema and edema after the lapse of time (72 hours after the administration) was quantified by the same method. Then, the value obtained by the Draize method was substituted into the following formula to calculate the primary irritation index (PII). The above results are shown in Table 6. The smaller the PII value, the smaller the skin irritation.
【００３６】一次刺激性インデックス P.I.I.=(A+B)/C
*2
A:投与後24時間経過時における紅斑及び浮腫の評価の合
計点
B:投与後72時間経過時における紅斑及び浮腫の評価の合
計点
C:例数（C=4）Primary irritation index PII = (A + B) / C
* 2 A: Total score for evaluation of erythema and edema 24 hours after administration B: Total score for evaluation of erythema and edema 72 hours after administration C: Number of cases (C = 4)
【００３７】[0037]
【表４】 [Table 4]
【００３８】[0038]
【表５】 検体処方 [Table 5] Sample prescription
【００３９】[0039]
【表６】 [Table 6]
【発明の効果】本発明により、熱安定性及び使用感に優
れた多価アルコール含有軟膏剤基剤を提供することが可
能となった。Industrial Applicability According to the present invention, it has become possible to provide a polyhydric alcohol-containing ointment base having excellent thermal stability and feeling during use.
【図１】 ＤＳＣ測定装置による融解曲線を示す。FIG. 1 shows a melting curve by a DSC measuring device.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 相川 勝義 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 (72)発明者 宇田 晴美 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 (72)発明者 中島 智子 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 Ｆターム(参考） 4C076 AA06 BB31 DD46A EE23A ─────────────────────────────────────────────────── ─── Continued front page (72) Inventor Katsuyoshi Aikawa 3-24-1, Takada, Toshima-ku, Tokyo Taisho product Yaku Co., Ltd. (72) Inventor Harumi Uda 3-24-1, Takada, Toshima-ku, Tokyo Taisho product Yaku Co., Ltd. (72) Inventor Tomoko Nakajima 3-24-1, Takada, Toshima-ku, Tokyo Taisho product Yaku Co., Ltd. F-term (reference) 4C076 AA06 BB31 DD46A EE23A
Claims (5)
体の60〜90質量％含有する軟膏剤基剤において、該多価
アルコール１質量部に対して25℃で固体状のポリエチレ
ングリコールを0.11〜0.66質量部含有することを特徴と
する軟膏剤基剤。1. An ointment base containing 60 to 90% by mass of a polyhydric alcohol in a liquid form at 25 ° C., wherein polyethylene glycol which is solid at 25 ° C. per 1 part by mass of the polyhydric alcohol is contained. An ointment base characterized by containing 0.11 to 0.66 parts by mass.
で液体状のポリエチレングリコール、プロピレングリコ
ール、ジプロピレングリコール、１，３−ブチレングリ
コール、グリセリン、エチレングリコール、ジエチレン
グリコール及びトリエチレングリコールからなる群より
選ばれる１種または２種以上である請求項１記載の軟膏
剤基剤。2. The polyhydric alcohol which is liquid at 25 ° C. is 25 ° C.
And 1 or 2 or more kinds selected from the group consisting of liquid polyethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, ethylene glycol, diethylene glycol and triethylene glycol. Ointment base.
が平均分子量4000〜20000のポリエチレングリコールで
ある請求項１記載の軟膏剤基剤。3. The ointment base according to claim 1, wherein the polyethylene glycol solid at 25 ° C. is polyethylene glycol having an average molecular weight of 4000 to 20000.
が平均分子量200〜600のポリエチレングリコールである
請求項２記載の軟膏剤基剤。4. The ointment base according to claim 2, wherein the polyethylene glycol liquid at 25 ° C. is a polyethylene glycol having an average molecular weight of 200 to 600.
温度が40℃以上であって、融解ピーク温度が40〜55℃の
範囲内にある請求項１〜４のいずれか１項に記載の軟膏
剤基剤。5. The melting start temperature when the temperature is raised at 1.0 ° C. per minute is 40 ° C. or higher, and the melting peak temperature is in the range of 40 to 55 ° C. The ointment base described in.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002117749A JP2003040763A (en) | 2001-05-23 | 2002-04-19 | Polyhydric alcohol-containing ointment base |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-153806 | 2001-05-23 | ||
| JP2001153806 | 2001-05-23 | ||
| JP2002117749A JP2003040763A (en) | 2001-05-23 | 2002-04-19 | Polyhydric alcohol-containing ointment base |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003040763A true JP2003040763A (en) | 2003-02-13 |
Family
ID=26615570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002117749A Pending JP2003040763A (en) | 2001-05-23 | 2002-04-19 | Polyhydric alcohol-containing ointment base |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2003040763A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5612306A (en) * | 1979-07-12 | 1981-02-06 | Nippon Zoki Pharmaceut Co Ltd | Novel base for external preparation |
| JPS5750914A (en) * | 1980-09-12 | 1982-03-25 | Shionogi & Co Ltd | Betamethasone external pharmaceutical |
| JPS62502471A (en) * | 1985-04-15 | 1987-09-24 | ロレアル | A novel naphthalene derivative with retinoid-type action, its production method, and pharmaceutical and cosmetic compositions containing the same |
| JPH06508100A (en) * | 1991-02-18 | 1994-09-14 | コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション | Composition for transdermal administration |
| JPH10158151A (en) * | 1996-11-29 | 1998-06-16 | Zeria Pharmaceut Co Ltd | Ointment containing sugaralcohols formulated therein |
| JPH11501629A (en) * | 1995-03-06 | 1999-02-09 | インターナショナル メディカル イノベーションズ インク． | Aqueous topical cream containing nitroglycerin; process for its production and use |
| JP2002205912A (en) * | 2001-01-12 | 2002-07-23 | Shiseido Co Ltd | Skin care preparation |
| JP2002241221A (en) * | 2001-02-16 | 2002-08-28 | Shiseido Co Ltd | Thermesthesia agent |
-
2002
- 2002-04-19 JP JP2002117749A patent/JP2003040763A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5612306A (en) * | 1979-07-12 | 1981-02-06 | Nippon Zoki Pharmaceut Co Ltd | Novel base for external preparation |
| JPS5750914A (en) * | 1980-09-12 | 1982-03-25 | Shionogi & Co Ltd | Betamethasone external pharmaceutical |
| JPS62502471A (en) * | 1985-04-15 | 1987-09-24 | ロレアル | A novel naphthalene derivative with retinoid-type action, its production method, and pharmaceutical and cosmetic compositions containing the same |
| JPH06508100A (en) * | 1991-02-18 | 1994-09-14 | コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション | Composition for transdermal administration |
| JPH11501629A (en) * | 1995-03-06 | 1999-02-09 | インターナショナル メディカル イノベーションズ インク． | Aqueous topical cream containing nitroglycerin; process for its production and use |
| JPH10158151A (en) * | 1996-11-29 | 1998-06-16 | Zeria Pharmaceut Co Ltd | Ointment containing sugaralcohols formulated therein |
| JP2002205912A (en) * | 2001-01-12 | 2002-07-23 | Shiseido Co Ltd | Skin care preparation |
| JP2002241221A (en) * | 2001-02-16 | 2002-08-28 | Shiseido Co Ltd | Thermesthesia agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI287994B (en) | Gelled aqueous cosmetic compositions | |
| WO1997002803A1 (en) | External skin preparation | |
| WO2009129627A1 (en) | Novel resveratrol compositions | |
| JPH10513179A (en) | Roll-on antiperspirant composition | |
| JPH11193208A (en) | Solubilized perfume-containing composition and composition for external use formulated therewith | |
| JP2004307491A (en) | Skin care preparation for external use containing heparinoid | |
| JPH08291049A (en) | Nonaqueous oily ointment base material and ointment for skin external use | |
| JP2005239678A (en) | Creamy preparation for external use having improved retainability in horny layer | |
| JP2008247754A (en) | Composition for external application | |
| US20060292245A1 (en) | Pain relief compositions | |
| JP2003040763A (en) | Polyhydric alcohol-containing ointment base | |
| JP5881879B1 (en) | External composition for improving acne vulgaris | |
| JPS5987035A (en) | W/o type emulsion composition stably containing urea | |
| JP4722683B2 (en) | Emulsion composition for skin | |
| JP3924017B2 (en) | Pharmaceutical composition for external use | |
| JP3675637B2 (en) | Composition for external use | |
| JP5109383B2 (en) | Adapalene-containing external preparation composition | |
| JP2001114651A (en) | Cosmetic composition | |
| JP4104296B2 (en) | Liquid oily cosmetics | |
| JP2002308729A (en) | Emulsion composition, emulsion cosmetic, medicine and antiallergic agent containing the same | |
| JP2002104927A (en) | Emulsion type solid cosmetic | |
| JPH069394A (en) | External antiphlogistic sedative liquid preparation | |
| JPS6391311A (en) | Gelatinous cosmetic | |
| JP2003313143A (en) | Polyhydric alcohol-containing base | |
| JP2006347954A (en) | Antiseptic for external application agent and dermal application composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090213 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090213 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090609 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100121 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100706 |